These companies are currently trading at low nominal prices with significant projected upside according to analysts and Zacks Investment Research .
: Trading around $4.03, this biotech firm has a forward P/E of 3.00. It is a high-growth play with projected 1-year EPS growth of over 150%.
: Currently priced at $2.97, Petco is viewed as a turnaround story with a projected EPS growth of 58% over the next year.
These companies are currently trading at low nominal prices with significant projected upside according to analysts and Zacks Investment Research .
: Trading around $4.03, this biotech firm has a forward P/E of 3.00. It is a high-growth play with projected 1-year EPS growth of over 150%.
: Currently priced at $2.97, Petco is viewed as a turnaround story with a projected EPS growth of 58% over the next year.
